Premium
Semaglutide: a new GLP‐1 analogue for type 2 diabetes
Author(s) -
Chaplin Steve
Publication year - 2019
Publication title -
prescriber
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.106
H-Index - 3
eISSN - 1931-2253
pISSN - 0959-6682
DOI - 10.1002/psb.1784
Subject(s) - medicine , semaglutide , type 2 diabetes , diabetes mellitus , endocrinology , liraglutide
Semaglutide (Ozempic) is a new once‐weekly glucagon‐like peptide‐1 (GLP‐1) analogue for the treatment of type 2 diabetes. This article examines its efficacy, adverse effects and place in therapy.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom